NCT02297139View on ClinicalTrials.gov

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

May 15, 2022

Study Completion Date

May 15, 2022

Conditions
Multiple Indications Cancer
Interventions
DRUG

Dasatinib

Trial Locations (6)

25000

Local Institution, Besançon

30-727

Local Institution - 0006, Krakow

41-500

Local Institution, Chorzów

93-510

Local Institution, Lodz

02776

Local Institution - 0003, Warsaw

50-367

Local Institution - 0002, Wroclaw

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY